
    
      This study consists of two parts. First part is a placebo-controlled multicenter,
      double-blind, parallel group study, in which subjects will receive ipragliflozin or placebo
      once daily in combination with an insulin preparation for 16 weeks. Second part is a
      multicenter, open-label period (36 weeks) with no placebo group. The dose of ipragliflozin
      can be doubled in combination with an insulin preparation during the second part.
    
  